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Epigenetic Modification of the Renin-Angiotensin System in
the Fetal Programming of Hypertension
Irina Bogdarina, Simon Welham, Peter J. King, Shamus P. Burns, Adrian J.L. Clark
Abstract—Hypertension is a major risk factor for cardiovascular and cerebrovascular disease. Lifelong environmental
factors (eg, salt intake, obesity, alcohol) and genetic factors clearly contribute to the development of hypertension, but
it has also been established that stress in utero may program the later development of the disease. This phenomenon,
known as fetal programming can be modeled in a range of experimental animal models. In maternal low protein diet
rat models of programming, administration of angiotensin converting enzyme inhibitors or angiotensin receptor
antagonists in early life can prevent development of hypertension, thus implicating the renin-angiotensin system in this
process. Here we show that in this model, expression of the AT1b angiotensin receptor gene in the adrenal gland is
upregulated by the first week of life resulting in increased receptor protein expression consistent with the increased
adrenal angiotensin responsiveness observed by others. Furthermore, we show that the proximal promoter of the AT1b
gene in the adrenal is significantly undermethylated, and that in vitro, AT1b gene expression is highly dependent on
promoter methylation. These data suggest a link between fetal insults to epigenetic modification of genes and the
resultant alteration of gene expression in adult life leading ultimately to the development of hypertension. It seems
highly probable that similar influences may be involved in the development of human hypertension. (Circ Res.
2007;100:520-526.)
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Although hypertension is recognized as 1 of the majorcontributing factors to cerebrovascular and cardiovascu-
lar disease,1 its pathogenesis remains incompletely under-
stood. Genetic and environmental factors clearly contribute to
this,2 but on current models fail to account entirely for the
disease. There is now substantial epidemiological evidence
that intrauterine stress may program the later development of
the disease.3 The phenomenon of fetal programming can be
modeled effectively in several mammalian species.4 Most
investigators have used models in which mothers are sub-
jected to relative undernutrition during pregnancy. Offspring
from these pregnancies exhibit later development of hyper-
tension, insulin resistance, glucose intolerance and frank
diabetes, the extent of each of these depending on the species
and experimental model.4
Administration of a low protein diet (8% protein in place of
18% protein in normal rat chow with the calorific content of
protein made up in the form of carbohydrate) to pregnant rats
either until term or weaning has been widely used in the
investigation of the pathogenesis of hypertension. This model
produces offspring of reduced birth weight in which elevated
systolic and diastolic blood pressures, as measured by tail
cuff methods or by indwelling carotid artery catheters, can be
identified as early as 4 weeks of age.5 Hypertension can be
prevented in this model by administration of angiotensin
converting enzyme inhibitors or angiotensin receptor antag-
onists, but not by nifedipene, between 2 and 4 weeks of age.6,7
This is highly suggestive of a role of the renin-angiotensin
system (RAS) in disease pathogenesis.
The consequence of the fetal insult in this and other
programming models is that the phenotype is altered in a
stable, but subtle manner. Such a phenotypic alteration
may be achieved either by a change in the number or
distribution of differentiated cells, or by changes in gene
expression by individual cells, and there is evidence to
support both occurrences.8 Following embryo implanta-
tion, the majority of the genome is demethylated.9 The
process of differentiation and development is accompanied
by the selective methylation of genes that are not needed
for function of the differentiated cell. As this process of
DNA methylation takes place in utero and in early post-
natal development, it is a good candidate for disturbance
by environmental interference, and thus provides a poten-
tial mechanism for fetal programming. Whereas methyl-
ation patterns are generally considered to be established in
early postnatal life and persist thereafter, there is evidence
from human monozygotic twin studies that methylation
patterns can change with ageing.10
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It has been shown that a maternal low protein diet is
associated with reduced global methylation, and it may be
that it is deficiency of specific amino acids, eg, glycine,
required to generate methyl donors, that underlies such
changes.11 Supplementation of low protein diets with glycine
or folate reverses the programming effect of those diets.12,13
However such a mechanism may lack gene specificity,
whereas other data argues that it is specific genes that are
susceptible to this effect.14–17
Thus in this study we set out to test the hypothesis that
alteration of DNA methylation of 1 or more RAS component
genes might underlie the alteration of gene expression that
culminated in the development of hypertension.
Materials and Methods
Animals
All animal procedures were conducted in an approved facility in
accordance with the Scientific Procedures (Animals) Act 1986, UK,
and were approved by the Institutional Animal Use Ethics Commit-
tee. The model of fetal programming and the phenotypic character-
istics of adult MLP rats have been described in detail.4 Briefly rat
dams (Wistar, Charles River, UK) were placed on either the normal
20% protein (control) rat chow or 8% protein (MLP, protein replaced
with carbohydrate) at conception. Offspring were randomly culled to
8 in each litter at birth (4 male, 4 female) and then weaned on to
identical (20% protein) rat chow at 3 weeks of age. Tissues (liver,
lung, kidney, whole brain, adrenal, heart) were harvested from all
members of a litter at 1, 4, or 12 weeks of age, and were immediately
deep-frozen in liquid nitrogen and stored at 80°C until further
analysis. Up to 3 litters were studied in each set of analyses.
RNA Isolation and Quantitation
Total RNA was isolated (QIAgen, Crawley, UK), quantitated, and
reverse-transcribed. Real-time QPCR was performed using a 2-step
cycling protocol: 95°C10 minutes, then 40 cycles of 95°C30s
and 59°C1 minute. Q-PCR analysis was conducted in optical
96-well plates with optical caps, using the MX4000 (Stratagene).
Primers and probes were designed to be intron-spanning wherever
possible. All probes were 5 labeled with 6-FAM as a reporter dye
and TAMRA as the 3 quencher. The 18S ribosomal RNA was used
as an internal reference control. Amplification plots were analyzed
using MX4000 software version 3.0 (Stratagene). RNA expression
data were given as copy number of gene of interest/g of RNA.
Standards used were PCR fragments purified from polyacrylamide
gel electrophoresis. All PCR reactions were performed in triplicate.
Gene specific primer and probe sequences are shown in Table I of
the online data supplement available at http://circres.ahajournals.org.
Immunoblotting
Rat adrenals were homogenized in RIPA buffer. Laemmli buffer
without mercaptoethanol was added to equal amounts of superna-
tants (50 g of protein). Proteins were incubated for 30 minutes at
55°C before being separated on SDS-PAGE and blotted onto PVDF
membranes. Membranes were incubated with a monoclonal AT1
receptor antibody (TONI-1, 1:400, Abcam, Cambridge, UK) or
rabbit anti-MAPK (1:1000, NEB, Hitchin, UK) as a loading control
and immune complexes were developed using enhanced chemilumi-
nescence reagents (Amersham Pharmacia Biotech, Chalfont St
Giles, UK).
Genomic DNA and Bisulphite Modification
Genomic DNA was isolated from whole adrenal or adrenal cortex
using DNAsol reagent (Invitrogen, Paisley, UK) or QIAamp minikit
(QIAgen). DNA was then digested with restriction enzymes EcoRV
and Bgl II (NEB), deproteinised with phenol/chloroform and ethanol
precipitated. DNA was treated with sodium bisulphite according to
modifications of the original protocol17 and as described.18 DNA was
ethanol precipitated, dissolved in 50 L water and used immediately
for PCR or stored at 20°C. PCR conditions were: 94°C12 min-
utes, then 40 cycles of 94°C30s, 52°C1 minute, 72°C30s and
finally 1 cycle of 7 minutes72°C. The reaction mixture contained
1Ampli Gold PCR buffer, 0.2 mmol/L dNTPs, 2 mmol/L MgCl2,
1 mol/L primers, 1.25 U of AmpliTaq Gold DNA polymerase
(Applied Biosystems, Warrington, UK) and 2 to 5 L DNA
template. Primer sequences are shown in supplemental Table II of the
online data supplement available at http://circres.ahajournals.org
Pyrosequencing
PCR and sequencing primers for pyrosequencing were designed
using PSQ Assay design software (Biotage AB, Uppsala). One of the
PCR primers was biotinylated, and the biotinylated strands were
purified and sequenced using the PSQTM 96MA 2.1 instrument
(Biotage AB). The primer sequences are listed in supplemental Table
II. Calibration curves were recorded using five mixtures of PCR
products (0, 25, 50, 75 and 100% methylation) prepared from cloned
fully methylated and unmethylated gene promoter region of the rat
AT1b receptor.
TOPO-TA Cloning and Sequencing
Gel sliced PCR products were passed through SNAP columns
(Invitrogen) and used immediately for TOPO- cloning according to
the manufacturers instruction (Invitrogen). Transformed TOP10 E.
coli cells were selected on LB-ampicillin (100 g/L) agar and
subjected to bacterial colony PCR. 15 independent clones containing
the appropriate sized insert for each amplified fragment were
sequenced on an ABI 3700 automated DNA sequencer (Applied
Biosystems) in accordance with the manufacturer’s instructions.
AT1b Promoter Analysis
A 1.2kb fragment (positions 277 to 1611 from Genbank U01033)
containing the rat AT1b receptor promoter was cloned into pGL3
basic (Promega). The promoter was methylated in vitro with 10 U of
SssI or Hha1 (NEB) according to the manufacturers instructions.
Controls included a mock methylated construct. 150 ng of each
plasmid were then cotransfected with 20 ng of the pRL-CMV Renilla
control vector (Promega) into mouse Y1 cells. After 24 hours cell
lysates were prepared and luciferase activity was measured using the
Dual-Luciferase reporter assay (Promega) and a Wallac Victor2 1420
Multilabel counter (Perkin Elmer, Finland). Reporter activity was
calculated by normalizing the reporter luciferase value to that of the
Renilla control vector. Site-directed mutagenesis of C residues at
CpG sites 1 to 3 in the modified AT1b promoter (positions 277 to
1454 from Genbank U01033) was performed using the QuickChange
Site-directed mutagenesis protocol (Stratagene) according to to the
manufacturer’s instructions. Mutations were confirmed by DNA
sequencing.
Statistical Analysis
Expression levels were compared using student’s 2-tailed t test and
methylation density in control and MLP adrenals was compared
using 2.
Results
Programmed and control animals from 10 control (5 male, 5
female) and 12 MLP (7 male, 5 female) offspring from 3
litters in each group were obtained as described and were
harvested for liver, lung, kidney, brain, heart, and adrenal
either at 1 or 12 weeks after birth. Real-time RT-PCR assays
for angiotensinogen, angiotensin converting enzyme (ACE),
renin, and the AT1a, AT1b, and AT2 angiotensin receptors were
performed. Absolute values for RNA copy number of angio-
tensinogen in the liver, renin in the kidney, ACE in the lung
and the 3 angiotensin receptors in the adrenal are shown in
Figure 1. Detailed results of all analyses are shown in
Bogdarina et al Epigenetics of Fetal Programming of Hypertension 521
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supplemental Table III. The only genes which showed a
significant increase in expression in maternal low protein
offspring (MLP) at both 1 and 12 weeks were the AT1a
angiotensin receptor in the female, but not the male kidney,
and the AT1b angiotensin receptor in the adrenal gland. RNA
copy number for this gene is considerably greater than that for
the other angiotensin receptors in this tissue. In contrast, the
AT2 receptor showed significant reduction of expression in
the adrenal at both 1 and 12 weeks in MLP offspring.
Confirmation that these changes resulted in changes in
receptor protein was provided by immunoblotting of adrenal
lysates using an antibody that recognizes both AT1a and AT1b
receptors which reveals significant differences on densitom-
etry (Figure 2). The histological appearance of the adrenal
was also investigated and shows no significant change in
structure or zonal distribution (Figure 3).
As the principal site of AT1b expression in the rat is the
adrenal zona glomerulosa (ZG)20,21 we prepared adrenal
capsules (which contain the majority of the ZG cell layer)
from 4 week old programmed and control animals and used
pooled tissue from one male and one female for methylation
analysis to focus on the 3 CpG sites in the proximal AT1b
promoter. Bisulphite converted DNA was subcloned and 30
individual clones from each group were sequenced This
showed significantly less methylation at the three potentially
methylatable sites in the proximal AT1b promoter (27.37;
P0.01) (Figure 4a and b). The alteration of AT1b gene
expression was confirmed in these same samples using
real-time RT-PCR (Figure 4c).
In view of the possibility that pooling might obscure the
variation between samples these studies were repeated in 4
week old animals from three independent litters in which
each animal’s whole adrenals were treated independently.
Bisulphite conversion, PCR and subcloning was performed as
before and revealed methylation at 21.8% of CpG sites in
control animals against 7.4% of sites in programmed animals.
Angiotensinogen - liver  Renin - kidney ACE - lung
AT1a - adrenal AT1b - adrenal AT2 - adrenal
1 wk   12 wk 1 wk      12 wk 1 wk    12 wk
1 wk    12 wk 1 wk    12 wk 1 wk    12 wk
RNA copy no./
g of total RNA
(x10  )3
RNA copy no./
g of total RNA
(x10  )3
b c
d e f
a
Figure 1. Altered expression of RAS genes in MLP
offspring. Real-time RT-PCR was used to quanti-
tate angiotensinogen, renin, ACE, and the AT1a,
AT1b, and AT2 angiotensin receptor mRNAs in vari-
ous control and MLP offspring rat tissues. Notable
shifts in expression at either 1 or 12 weeks of age,
or both, were demonstrated (a) for angiotensino-
gen in liver, (b) renin in kidney, and (d, e, and f) the
3 angiotensin receptors in the adrenal. Note the
different range of the y axis scale. No changes in
ACE expression were apparent (c). Data are
expressed as RNA copy number per g of total
RNA. White columns, control animals; black col-
umns, MLP animals. *P0.05; **P0. 01;
***P0.001.
MAPK
AT1
a
Control             MLP
1 2 3 1 2 3 4
R
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*
Figure 2. a, Immunoblot of AT1a and b receptor in whole adrenal from control and MLP rats at 12 weeks age. Total MAPK is used as a
loading control. b, Densitometric quantitation of (a), corrected for protein loading and mean valuesSD for 3 control (white bar) and 4
MLP adrenals (shaded bar) are shown. *P0.05
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These results are shown in Figure 4d and are significantly
different when assessed as a group (all 3 sites considered,
27.73, P0.05) or in the case of sites 1 and 3 when
considered individually (site 1, 211.88, P0.01; site 3,
27.65, P0.05). Pyrosequencing analysis of this same
region confirmed a similar significant reduction in methyl-
ation of each of the three sites (data not shown).
Analysis of 17 CpG sites in the AT1a promoter and first
exon using Pyrosequencing showed only occasional methyl-
ation of site 13 (position 3278 in rat AT1a sequence; accession
number S66402) and approximately 20% methylation of site
14 (position 3264), both located in exon 1. There was no
difference in methylation frequency at this site between 5
MLP and 4 control offspring. There was no methylation of
any other CpG site in this promoter in the adrenal.
The influence of methylation of the AT1b promoter on gene
expression was demonstrated by transfection of 1.2 Kbp of
the AT1b promoter coupled to a luciferase reporter gene into
mouse adrenocortical Y1 cells. Treatment of this promoter
with the site-specific Hha1 methylase or the nonspecific CpG
methylase Sss1 before transfection results in methylation of
either 1 or all 6 CpG sites respectively in this fragment, and
in the latter case is associated with markedly reduced pro-
moter activity. When the 3 proximal sites analyzed for
methylation were mutated so that they could no longer be
modified by Sss1, significant loss of promoter activity was
observed. Methylation of the 3 remaining upstream CpG sites
with Sss1 had no further influence. The contribution of each
of the three proximal sites, and notably site 3 is revealed by
analysis of the effect of their individual mutation without
methylation (Figure 5).
Discussion
We show here that offspring of mothers fed a low protein diet
develop increased expression of the AT1b receptor mRNA and
protein in the adrenal. The antibody used in immunoblotting will
detect the AT1a receptor equally well, but as the relative
expression of AT1b at the mRNA level in these adrenal glands is
much greater we believe that the majority of receptor protein
identified on immunoblotting is the AT1b form. Similar findings
of increased AT1 receptor expression have been reported in
sheep following maternal protein deprivation.22 Moreover it has
also been shown that the MLP rat adrenal is more responsive to
angiotensin II (Ang II).23 Importantly we show that these
changes are apparent very early in the life of programmed
offspring and persist until at least 12 weeks of age. Certain genes
(angiotensinogen, renin and AT1a receptor in kidney and AT1a
and AT2 receptor in the adrenal) show significant changes in
expression at 12 weeks of age which may relate to the early
consequences of developing hypertension. Other genes such as
angiotensinogen and the AT1a receptor in the liver show in-
creased expression at 1 week of age which has normalized by 12
weeks. We speculate that this may reflect recovery from the
period of relative undernutrition. These studies were not set up to
investigate sex differences in gene expression, but it is interest-
ing to note that female rats show significantly increased AT1a
expression in the MLP kidney at both 1 and 12 weeks of age and
this observation may be worthy of further investigation.
Interestingly, expression of the AT1b receptor is similar or
reduced in the spontaneously hypertensive rat when compared
with control Wistar Kyoto rats, probably as an adaptive re-
sponse.24 Because this receptor mediates the action of the
peptide Ang II to stimulate adrenal aldosterone production, it is
likely to contribute to the subsequent development of hyperten-
sion. Furthermore, it has been shown that blockade of Ang II
production with ACE inhibitors, or interaction with the AT1
receptor using a receptor antagonist will prevent development of
hypertension in MLP offspring in contrast to nifedipene.6,7
These findings confirm an important, if not unique, role for this
receptor in this model. Investigation of the role of the AT1b
receptor in mice in which 1 or the other, or both AT1 receptors
have been deleted suggests the AT1b receptor contributes to
blood pressure maintenance and in the absence of AT1a receptors
mediates a pressor response to angiotensin 25–27
Two possible explanations for increased receptor expres-
sion are conceivable. Expression of the AT1b receptors in the
rat adrenal is almost entirely restricted to the ZG, and fetal
hyperproliferation of this cell type might be consistent with
the increased quantity of AT1b mRNA expressed in the
adrenal. Differentiation of the rat ZG cells is first apparent
just before birth28,29 and although this might be influenced by
the continuation of the low protein diet during suckling, the
hypertensive phenotype can equally be observed in animals
that receive the low protein diet in pregnancy alone. However
histological examination of the adrenal (Figure 3) shows no
apparent ZG hyperplasia and MLP animals cannot be distin-
guished from controls.
A second explanation for increased AT1b receptor gene
expression is that the fetal insult has induced a persistent
modification of AT1b gene expression. Altered DNA methyl-
ation has long been proposed as a candidate mechanism for
fetal programming, although there are few examples in which
Figure 3. Adrenal histology from control
(a) and MLP rat (b) at 10X magnification.
ZGzona glomerulosa; ZFRzona fas-
ciculata and reticularis. Scale bar repre-
sents 100 m.
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this has been directly demonstrated by bisulphate sequenc-
ing14,16 or inferred from methylation sensitive PCR analy-
sis,15,17 and at least one case in which increased gene
expression appears to be independent of DNA methylation.19
We have shown here that the AT1b gene promoter, which
quite clearly is highly susceptible to regulation by DNA
methylation, is indeed less methylated in programmed ani-
mals. The present work demonstrates a direct link between
maternal environmental factors that cause hypertension and
epigenetic modification of a gene promoter.
It is interesting to note that the proportion of AT1b
methylation in the adrenal capsule, representing a rela-
tively pure ZG cell preparation (Figure 4b), is not highly
different from that in the whole adrenal (Figure 4d). The
most likely explanation for this is that all adrenocortical
cells develop from a stem cell in which the AT1b methyl-
ation pattern has been set.30 Thus the methylation pattern
in the ZG cell would be reflected in cells in the fasciculata
and reticularis cell layers, even though these cells do not
express the receptor.
The molecular mechanisms that underlie such an alteration
in methylation pattern as a result of fetal programming
remain to be determined. One proposal is that undernutrition
leads to deficiency of methyl donors and, conceivably, certain
genes might be more susceptible to this influence than
others.8 A substantial body of evidence suggests that pro-
grammed phenomena can result from excessive glucocorti-
coid action either when directly administered to pregnant
dams or as a result of maternal stress.31 Whether such an
occurrence can influence the normal process of DNA meth-
Programmed
site 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
-100Sp1 Sp1AP1 InrNF-1-50
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*** Figure 4. Methylation analysis of theAT1b promoter. a, Structure of the AT1b
proximal promoter region showing
location of putative transcription start
site, consensus sequences for potential
transcription factors and CpG methyl-
ation sites (open circles) analyzed in
this study numbered 1 to 3.
InrInitiator element. b, Methylation of
adrenal capsule AT1b gene in control
and MLP animals. Eunmethylated;
●methylated. One male and 1 female
from each group had adrenal capsules
harvested and used in this analysis. c,
Expression of AT1b mRNA in these
same adrenal capsule samples
expressed relative to 18S RNA. Control
rats, white bar; MLP rats, shaded bar.
***P0.0001. d, Methylation of AT1b
gene proximal promoter in individual
adrenals from six different animals in
each group at 4 weeks of age. Each
column represents an individual ani-
mal’s adrenal in which methylation sta-
tus is determined at each of the 3 sites
of interest. Fifteen clones were exam-
ined from each adrenal.
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ylation remains to be determined. The data obtained using in
vitro methylation shown in Figure 5 argue that CpG site 3 has
a particularly potent influence on promoter activity in that
when mutated or methylated the promoter is essentially
inactive. This base is at the center of an Sp1 consensus site,
suggesting that failure to bind this, or a related transcription
factor may have a crucial impact. However it is generally
considered that Sp1 binding is not influenced by DNA
methylation32 although there are exceptions to this33 and it is
possible that another methylation sensitive transcription fac-
tor binds here.
The human genome only contains a single AT1 receptor
gene which is widely expressed in a pattern similar to that of
the AT1a receptor.34 There is no human equivalent to the
relatively adrenal-specific AT1b receptor. Thus these findings
may be difficult to translate directly into the human hyper-
tensive scenario. Furthermore there is also data derived from
human monozygotic twin studies that challenges the view
that methylation patterns are established in early life and
remain unchanged thereafter.10 Nevertheless, the possibility
that maternal undernutrition may result in highly specific
altered methylation patterns in the offspring provides in-
creased mechanistic understanding worthy of investigation in
man.
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Online Table 1 
Sequence of DNA oligonucleotide primers and probes used in RNA quantitation experiments 
 
 
GENE PRIMERS and PROBES 
 
RENIN  
NM_012642   
5’ (F) GTAACTGTGGGTGGAATCATTGTG  
5’ (R) TGGGAGAGAATGTGGTCGAAGA 
 probe TTGGAGAGGTCACCGAGCTGCCCC 
 
AT1A  
M86912   
5’ (F) GGAGAGGATTCGTGGCTTGAG 
5’ (R) CTTTCTGGGAGGGTTGTGTGAT 
probe TTCCACCCGATCACCGATCACCGG 
 
AT1B  
M90065  
5’ (F) TTGTCCACCCAATGAAGTCTCG 
5’ (R) CGCAAACTGTGATATTGGTGTTCT 
probe CCGCCGCACGATGCTGGTAGCC 
 
AT2  
D16840 
5’ (F) CATCACCAGCAGTCTTCCTTTTG 
5’ (R) AAAACAGTGAGACCACAACAATGT 
probe CGCAACTGGCACCAATGAGTCCGC 
 
ACE  
NM_12544 
5’ (F) CGGGTCGCAGAGGAATTCTT 
5’ (R) CCTGAAGTCCTTCCTGTTGTAGA 
probe CACGCAGAGGCATGGCACACCACC 
 
Angiotensinogen  
NM_134432 
5’ (F) AGAACCCCAGTGTGGAGACG  
5’ (R) AGCCAACCTTTGAGCCTGTGCCCA 
probe  AGCCAACCTTTGAGCCTGTGCCCA 
 
 
 
 
 by on March 12, 2009 circres.ahajournals.orgDownloaded from 
Online Supplement                                                                                                    Bogdarina et al. 
                                                                            Epigenetics of fetal programming of hypertension 
 2
Online Table 2 
Primers used for AT1a (top) and AT1b (bottom) bisulphate sequencing and pyrosequencing 
 
 
GENE PRIMERS 
 
AT1A 
Amplification 
 
F1A   5’- TGTTAGTATTTTGATTTAGATGTGG            
R1A   5’- CATATAACCTTATACCCACCTC-biotin 
F2A   5’- TGTTTGGAGGTTAGTAGTTAG  
R2A 5’- AACCTAAAAATTAAAACCTACAAAACAA-biotin   
 
 
AT1A 
Pyrosequencing 
 
SeqF(6-12)  5’- AATGTGGTAGAGTTGAGAGA 
SeqF(13-14) 5’- GGGTGGAATAGGATTTAAG  
SeqF(15-16) 5’- TTTATATTTATAGTTTAGGG 
SeqF(17-19) 5’- GTTTTGTAGGTTTTAATTTT 
SeqF(20-22) 5’- TTTGAGATTTTTTGTTTAAT 
 
 
 
 
 
GENE PRIMERS 
 
AT1B 
Amplification 
 
FB –5’ GATTTTTTTTTATAATTTTTTTAAGGTGG 
RB– 5’CAAATAAACCTATATCAAATAAATAACAC. 
 
 
AT1B                  
Pyrosequencing 
 
Fp – 5’ATTTTTTGTTGTTTGGGATTTAGG 
Rp – 5’CATTCCAAACCCAAATAAACCTAT-biotin 
SeqF(1-3)  - 5’TTAATTTATTTAGTAAAGGG 
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Online Table 3 
Values of RNA copy number/µg RNA of all genes analysed in this study at 1 and 12 weeks of age 
 
 
Angiotensinogen 
 
   1 week     12 weeks 
  Control MLP   Control MLP  
 
Liver   
Mean  54060  105000   80570  87060 
SD  5657  10010   4574  10940 
N  4  4   4  4 
   P<0.001    NS 
 
Kidney 
Mean  Low values    1688  5058    
SD       316  188 
N       4  4 
        P<0.001 
 
Lung  Low values    Low values 
Mean 
SD 
N 
 
 
Brain 
Mean  1501  934   4445  1839 
SD  535  579   3322  1116 
N  3  3   6  6  
   NS     NS 
 
Heart  Not done    Not done 
Mean 
SD 
n 
 
 
Adrenal 
Mean  969  522   242  256 
SD  169  103   14  47 
n  4  4   4  4 
   p = 0.004    NS 
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Renin 
 
   1 week     12 weeks 
  Control MLP   Control MLP  
 
Liver  Not done    Not done 
Mean   
SD   
N   
 
Kidney 
Mean  27170  25640   55770  244800 
SD  6250  7469   28440  76450 
N  8  8   8  8 
   NS     p<0.001 
 
 
Kidney (Male)  
Mean  26820  24980   80640  305100   
SD  2529  6525   13300  45990 
N  4  4   4  4 
   NS     p<0.001 
 
Kidney (Female)  
Mean  27510  26300   30900  184400 
SD  9189  9297   7850  42650 
N  4  4   4  4 
   NS     p<0.001 
 
 
Lung  Not done    Not done 
Mean 
SD 
N 
 
 
Brain  Low values    Low values 
Mean 
SD 
N 
 
 
Heart  Not done    Not done 
Mean 
SD 
N 
 
 
Adrenal Low values    Low values 
Mean   
SD   
N   
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ACE 
 
   1 week     12 weeks 
  Control MLP   Control MLP  
 
Liver  Not done    Not done 
Mean   
SD   
N   
 
 
Kidney 
Mean  349300  328500   340500  333000 
SD  81700  44300   78700  37500 
N  4  4   4  4 
   NS     NS 
 
Lung 
Mean  2708000 2464000  2832000 2664000 
SD  747700  519300   834800  553700 
N  5  5   5  5 
   NS     NS 
 
Brain  Not done    Not done 
Mean 
SD 
N 
 
 
Heart  Not done    Not done 
Mean 
SD 
N 
 
 
Adrenal Not done    Not done 
Mean   
SD   
N   
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AT1a receptor 
 
   1 week     12 weeks 
  Control MLP   Control MLP  
 
Liver   
Mean  19410  38020   87830  118100 
SD  2792  5042   8841  19880 
N  3  3   3  3 
   p = 0.005    NS 
 
Kidney 
Mean  16160  16780   8035  17360 
SD  1067  5111   5608  4455 
N  6  6   9  9 
   NS     p = 0.001 
 
Kidney (Male)  
Mean  16250  12470   12170  18480 
SD  985  2481   3736  4645 
N  3  3   5  5  
   NS     p = 0.045 
 
Kidney (Female)  
Mean  16080  21090   2863  15960 
SD  1361  1862   1027  4412 
N  3  3   4  4 
   P = 0.02    p = 0.001 
 
Lung  Low values    Low values 
Mean 
SD 
N 
 
 
Brain  Not done    Low values 
Mean 
SD 
N 
 
 
Heart  Not done    Not done 
Mean 
SD 
N 
 
 
Adrenal 
Mean  13730  15990   1700  3885 
SD  2273  2986   317  878 
N  4  4   3  3 
 
   NS    p = 0.015 
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AT1b receptor 
 
 
   1 week     12 weeks 
  Control MLP   Control MLP  
 
Liver  Low values    Low values 
Mean   
SD   
N   
 
 
Kidney  Low values     
Mean       18790  16480 
SD       19410  11880 
N       6  6 
 
 
Lung  Low values    Low values 
Mean 
SD 
N 
 
 
Brain  Low values    Low values 
Mean 
SD 
N 
 
 
Heart  Low values    Low values 
Mean 
SD 
N 
 
 
Adrenal 
Mean  99430  182000   186000  678800 
SD  4410  4593   12800  224000 
N  4  4   4  4 
   p = 0.04    p = 0.004 
 
 
 by on March 12, 2009 circres.ahajournals.orgDownloaded from 
Online Supplement                                                                                                    Bogdarina et al. 
                                                                            Epigenetics of fetal programming of hypertension 
 8
AT2 receptor 
 
   1 week     12 weeks 
  Control MLP   Control MLP  
 
Liver  Low values    Low values 
Mean   
SD   
N   
 
 
Kidney       Not done 
Mean  13810  17710 
SD  5888  1079 
N  6  6 
   NS 
 
Lung  Not done    Not done 
Mean 
SD 
N 
 
 
Brain  Not done    Not done 
Mean 
SD 
N 
 
 
Heart  Low values    Low values     
Mean 
SD 
N 
 
 
Adrenal 
Mean  71730  25350   54380  36100 
SD  10560  2700   15980  2934 
N  6  6   6  6 
   p<0.001    p = 0.02 
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